Galectin Therapeutics, Inc. (GALT)
3.43
-0.06
(-1.86%)
USD |
NASDAQ |
Oct 20, 16:00
3.43
0.00 (0.00%)
After-Hours: 20:00
Galectin Therapeutics Research and Development Expense (TTM) : 8.91M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 8.91M |
| March 31, 2026 | 10.04M |
| December 31, 2025 | 14.29M |
| September 30, 2025 | 23.47M |
| June 30, 2025 | 28.45M |
| March 31, 2025 | 35.00M |
| December 31, 2024 | 36.57M |
| September 30, 2024 | 33.69M |
| June 30, 2024 | 33.83M |
| March 31, 2024 | 31.38M |
| December 31, 2023 | 32.13M |
| September 30, 2023 | 32.91M |
| June 30, 2023 | 31.78M |
| March 31, 2023 | 32.48M |
| December 31, 2022 | 31.74M |
| September 30, 2022 | 28.59M |
| June 30, 2022 | 28.60M |
| March 31, 2022 | 26.98M |
| December 31, 2021 | 23.82M |
| September 30, 2021 | 24.33M |
| June 30, 2021 | 22.50M |
| March 31, 2021 | 20.73M |
| December 31, 2020 | 17.98M |
| September 30, 2020 | 15.40M |
| June 30, 2020 | 12.12M |
| Date | Value |
|---|---|
| March 31, 2020 | 8.965M |
| December 31, 2019 | 7.467M |
| September 30, 2019 | 4.863M |
| June 30, 2019 | 4.865M |
| March 31, 2019 | 4.819M |
| December 31, 2018 | 6.471M |
| September 30, 2018 | 6.281M |
| June 30, 2018 | 8.279M |
| March 31, 2018 | 10.25M |
| December 31, 2017 | 11.72M |
| September 30, 2017 | 14.15M |
| June 30, 2017 | 13.94M |
| March 31, 2017 | 14.72M |
| December 31, 2016 | 15.32M |
| September 30, 2016 | 14.81M |
| June 30, 2016 | 15.98M |
| March 31, 2016 | 14.36M |
| December 31, 2015 | 13.11M |
| September 30, 2015 | 12.28M |
| June 30, 2015 | 9.795M |
| March 31, 2015 | 8.789M |
| December 31, 2014 | 8.425M |
| September 30, 2014 | 7.74M |
| June 30, 2014 | 6.953M |
| March 31, 2014 | 6.708M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Mirum Pharmaceuticals, Inc. | 282.06M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| Anika Therapeutics, Inc. | 27.45M |
| Savara, Inc. | 86.84M |